CAR T cell therapy targeting CD19: Phase I started

Ziopharm began an open-label, U.S. Phase I trial to evaluate IV CAR T cell therapy targeting CD19 over 1-2 days in about 30 patients. Ziopharm has exclusive, worldwide rights to the human in vivo effe...